Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Publisher: La Merie Publishing
Pages: 53
Format: PDF
Product Code: LMCA0165
Release Date: March of 2018

80.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

La Merie Publishing released on March 9, 2018 the 12th edition of reports about sales of Blockbuster Biologics. This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2017. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 8, 2017. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

A total of 45 biologic therapeutics reached blockbuster status with 2017 sales exceeding US$ 1 bln: 27 antibodies and 18 proteins. Fourteen new biologics with sales data were included fort he first time in this compilation. Ten biologics reached global sales in 2017 of more than US$ 5 bln. Three biologics were new in the blockbuster biologics list. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2017 sales higher than US$ 1 bln. Another ranking list was prepared for TOP 30 companies according to biologics sales in 2017 and the percentage of antibody sales of total biologics sales.

Blockbuster Biologics 2017

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Table of Contents

2017 Biologics Sales per Class of Branded Originator Products

Blockbuster Biologics in 2017 (by generic name)

TOP 30 Company Ranking List for Biologics Sales 2017

Currency Exchange Rates

Biologic Product Sales 2017

  • Cancer Antibodies
  • Anti-TNF Antibodies
  • Other Anti-Inflammatory and Anti-Autoimmune Antibodies
  • Insulin and Insulin Analogs
  • Ophthalmic Antibodies
  • Recombinant Coagulation Factors
  • Cardiometabolic & Anti-Infective Antibodies
  • Enzyme Replacement Proteins (ERT)
  • Erythropoietins
  • G-CSF
  • Interferon beta
  • Human Growth Hormone (hGH)
  • Follicle Stimulating Hormone (FSH)
  • Other Proteins: Cardiometabolic, Cancer & Others
  • Selected Biosimilar Antibodies & Proteins

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up